Search research articles
Contact Us
Filters
Showing results (41-50 of 50) with videos related to
Page
of 5
Sort By:
You have reached the last page of results.
This site can display upto 50 results.
Frontiers in Oncology
|
October 20, 2025
Case Report: Could genetic factors influence the outcomes of first-line enfortumab vedotin plus pembrolizumab therapy in patients with metastatic urothelial carcinoma? Two cases of patients harbouring a BRCA mutation
Giuseppe Salfi, Chiara Maria Agrippina Clerici, Giovanna Pecoraro, et al.
Cancer Chemotherapy and Pharmacology
|
June 15, 2024
Population pharmacokinetics of TLD-1, a novel liposomal doxorubicin, in a phase I trial
Anna M Mc Laughlin, Dagmar Hess, Robin Michelet, et al.
Nature Communications
|
May 13, 2026
Maveropepimut-S, pembrolizumab and low dose cyclophosphamide in metastatic ovarian cancer: phase 1/2 PESCO trial
Ana C Veneziani, Stephanie Lheureux, Douglas G Millar, et al.
Clinical Pharmacokinetics
|
November 18, 2025
TLD-1, a Novel Liposomal Doxorubicin, in Patients with Solid Tumors: Comparative Pharmacokinetics and Final Results of a Multicenter Phase 1 Study (SAKK 65/16)
Marian Klose, Ilaria Colombo, Katrin Gobat, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 22, 2026
Debio 0123, a WEE1 kinase inhibitor: Phase 1 results from dose escalation in patients with advanced solid tumors
Kyriakos P Papadopoulos, Manish R Sharma, Reinhard Dummer, et al.
Cancer Research Communications
|
March 6, 2023
Repurposing Itraconazole and Hydroxychloroquine to Target Lysosomal Homeostasis in Epithelial Ovarian Cancer
Stefano Marastoni, Ainhoa Madariaga, Aleksandra Pesic, et al.
Journal for Immunotherapy of Cancer
|
March 15, 2022
Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer
Stephanie Lheureux, Daniela E Matei, Panagiotis A Konstantinopoulos, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
December 13, 2025
ESMO-ESTRO consensus statements on the safety of combining radiotherapy with CDK4/6, HER2, PARP, or mTOR inhibitors
Evert S M van Aken, Ajeet Kumar Gandhi, Sean M O'Cathail, et al.
Journal for Immunotherapy of Cancer
|
March 15, 2019
An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE)
Derek L Clouthier, Scott C Lien, S Y Cindy Yang, et al.
Nature
|
October 16, 2023
Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance
Christina Guo, Adam Sharp, Bora Gurel, et al.
Page
of 5
Search research articles
Search
Showing results (41-50 of 50) with videos related to
Sort By:
Page
of 5
You have reached the last page of results.
This site can display upto 50 results.
Frontiers in Oncology
|
October 20, 2025
Case Report: Could genetic factors influence the outcomes of first-line enfortumab vedotin plus pembrolizumab therapy in patients with metastatic urothelial carcinoma? Two cases of patients harbouring a BRCA mutation
Giuseppe Salfi, Chiara Maria Agrippina Clerici, Giovanna Pecoraro, et al.
Cancer Chemotherapy and Pharmacology
|
June 15, 2024
Population pharmacokinetics of TLD-1, a novel liposomal doxorubicin, in a phase I trial
Anna M Mc Laughlin, Dagmar Hess, Robin Michelet, et al.
Nature Communications
|
May 13, 2026
Maveropepimut-S, pembrolizumab and low dose cyclophosphamide in metastatic ovarian cancer: phase 1/2 PESCO trial
Ana C Veneziani, Stephanie Lheureux, Douglas G Millar, et al.
Clinical Pharmacokinetics
|
November 18, 2025
TLD-1, a Novel Liposomal Doxorubicin, in Patients with Solid Tumors: Comparative Pharmacokinetics and Final Results of a Multicenter Phase 1 Study (SAKK 65/16)
Marian Klose, Ilaria Colombo, Katrin Gobat, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 22, 2026
Debio 0123, a WEE1 kinase inhibitor: Phase 1 results from dose escalation in patients with advanced solid tumors
Kyriakos P Papadopoulos, Manish R Sharma, Reinhard Dummer, et al.
Cancer Research Communications
|
March 6, 2023
Repurposing Itraconazole and Hydroxychloroquine to Target Lysosomal Homeostasis in Epithelial Ovarian Cancer
Stefano Marastoni, Ainhoa Madariaga, Aleksandra Pesic, et al.
Journal for Immunotherapy of Cancer
|
March 15, 2022
Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer
Stephanie Lheureux, Daniela E Matei, Panagiotis A Konstantinopoulos, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
December 13, 2025
ESMO-ESTRO consensus statements on the safety of combining radiotherapy with CDK4/6, HER2, PARP, or mTOR inhibitors
Evert S M van Aken, Ajeet Kumar Gandhi, Sean M O'Cathail, et al.
Journal for Immunotherapy of Cancer
|
March 15, 2019
An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE)
Derek L Clouthier, Scott C Lien, S Y Cindy Yang, et al.
Nature
|
October 16, 2023
Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance
Christina Guo, Adam Sharp, Bora Gurel, et al.
Page
of 5